New pillars of optimal medical treatment in heart failure

Prof. Michael Böhm explains how SGLT-2 inhibitors became a strong pillar of treatment in HFrEF and HFpEF patients. Their antidiabetic effect and kidney protection make them a widely used tool in cardiovascular diseases. We learn where GLP-1 agonists stand in cardiovascular risk protection and how beneficial they are in overweight HFpEF patients. The new mineralocorticoid receptor antagonists (MRAs) also proved their role in HF treatment. The new, non-steroid MRA, finerenone improved CV outcomes in the FINEARTS-HF trial in HFpEF patients, presented at ESC2024. The MOONRAKER program will further investigate finerenone’s place in HF therapy. He stresses that we must use all 4 pillars of HF treatment.

Pre-diabetes: a risk factor for cardiovascular disease? - report from ESC2024

Professor Antonio Ceriello co-chaired a very interesting session on prediabetes. He shared his thoughts on the field with us.

What is the benefit of starting earlier PCSK9 inhibitors for acute coronary syndromes? - report from ESC2024

Professor Marc Bonaca explains what is the benefit of starting earlier PCSK9 inhibitors for acute coronary syndromes?

2024 ESC Guidelines for the Management of Chronic Coronary Syndromes

Professor Christiaan Vrints co-chaired the guideline task force on the 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes.

2024 ESC Guidelines for the Management of Atrial Fibrillation

Professor Isabelle C. Van Gelder co-chaired the guideline task force on the 2024 ESC Guidelines for the Management of Atrial Fibrillation.

Cardiovascular multimorbid patients’ care

Professor Claudio Borghi shares his insights on cardiovascular multimorbid patients’ care.

Guidelines in Practice: implementing the 2023 Focused Update on Heart Failure - target, treat, and titrate

Professor Piotr Ponikowski shares his experiences on ESC Clinical Practice Guidelines in implementing the 2023 Focused Update on Heart Failure.

Patient engagement in lipid-lowering therapies

Professor Vera Bittner shares her experiences in patient engagement in lipid-lowering therapies.

Chronic ischaemic syndrome management in 2024: are we ready for the (r)evolution?

Professor Mario Marzilli highlights the evolving environment of chronic coronary syndrome management and translates new ESC chronic coronary syndrome guidelines into clinical practice.

FINE-HEART - Participant-level pooled analysis of finerenone in heart failure and chronic kidney disease trials

Professor Muthiah Vaduganathan explains that the FINE-HEART pooled analysis of three large trials failed to demonstrate significant reductions in cardiovascular death with finerenone, but significantly lower all-cause mortality, cardiovascular events and kidney outcomes were observed, according to late-breaking research presented in a Hot Line session at ESC Congress 2024.

EPIC-CAD - Edoxaban monotherapy vs. dual antithrombotic therapy for atrial fibrillation and stable coronary artery disease - report from ESC2024

Professor Gi-Byoung Nam explains thtat edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial fibrillation and stable coronary artery disease, according to late-breaking research presented in a Hot Line session at ESC Congress 2024.

Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis

Professor Pardeep Jhund explains that mineralocorticoid receptor antagonists reduced the risk of cardiovascular death or heart failure hospitalization in patients with HF and reduced ejection fraction and also in those with mildly reduced or preserved ejection fraction, according to late-breaking research presented in a Hot Line session at ESC Congress 2024.

ESC Clinical Practice Guidelines 2022 and 2023 for General Practice and General Cardiology: where do we stand?

Professor Konstantinos Toutouzas co-chaired an interresting session for general clinicians the ESC Guidelines on Cardio-Oncology and Management of Cardiovascular Disease in Patients with Diabetes.

Beta blocker interruption in patients with prior myocardial infarction: results of the ABYSS trial and effect on blood pressure and heart rate control

Professor Johanne Silvain presented results of the ABYSS trial in a Hot Line session at ESC Congress 2024. The cardiovascular safety of interrupting beta-blocker could not be shown in comparison to continuation in patients with a history of myocardial infarction and there was no benefit to the patients’ quality of life, according to late-breaking research presented.

The Dundee experience: really personalised acute stroke treatment!

Professor Iris Grunwald shares her experience of personalised stroke management.

2024 ESC Guidelines for the Management of Peripheral Arterial and Aortic Diseases

Professor José Rodriguez Palomares co-chaired the guideline task force on 2024 ESC Guidelines for the Management of Peripheral Arterial and Aortic Diseases.